| Literature DB >> 31779109 |
Ibukun Ogunade1, Yun Jiang2, Andres Pech Cervantes3.
Abstract
The study applied a targeted metabolomics approach that uses a direct injection and tandem mass spectrometry (DI-MS/MS) coupled with a liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based metabolomics of plasma to evaluate the effects of supplementing clay with or without Saccharomyces cerevisiae fermentation product (SCFP) on the metabolic status of dairy cows challenged with aflatoxin B1. Eight healthy, lactating, multiparous Holstein cows in early lactation (64 ± 11 DIM) were randomly assigned to one of four treatments in a balanced 4 × 4 duplicated Latin square design with four 33 d periods. Treatments were control, toxin (T; 1725 µg aflatoxin B1 (AFB1)/head/day), T with clay (CL; 200 g/head/day), and CL with SCFP (YEA; 35 g of SCFP/head/day). Cows in T, CL, and YEA were dosed with aflatoxin B1 (AFB1) from days 26 to 30. The sequestering agents were top-dressed from day 1 to 33. On day 30 of each period, 15 mL of blood was taken from the coccygeal vessels and plasma samples were obtained from blood by centrifugation and analyzed for metabolites using a kit that combines DI-MS/MS with LC-MS/MS-based metabolomics. The data were analyzed using the GLIMMIX procedure of SAS. The model included the effects of treatment, period, and random effects of cow and square. Significance was declared at p ≤ 0.05. Biomarker profiles for aflatoxin ingestion in dairy cows fed no sequestering agents were determined using receiver-operator characteristic (ROC) curves, as calculated by the ROCCET web server. A total of 127 metabolites such as amino acids, biogenic amines, acylcarnitines, glycerophospholipids, and organic acids were quantified. Compared with the control, T decreased (p < 0.05) plasma concentrations of alanine, leucine, and arginine and tended to decrease that of citrulline. Treatment with CL had no effects on any of the metabolites relative to the control but increased (p ≤ 0.05) concentrations of alanine, leucine, arginine, and that of citrulline (p = 0.07) relative to T. Treatment with YEA resulted in greater (p ≤ 0.05) concentrations of aspartic acid and lysine relative to the control and the highest (p ≤ 0.05) plasma concentrations of alanine, valine, proline, threonine, leucine, isoleucine, glutamic acid, phenylalanine, and arginine compared with other treatments. The results of ROC analysis between C and T groups revealed that the combination of arginine, alanine, methylhistidine, and citrulline had sufficient specificity and sensitivity (area under the curve = 0.986) to be excellent potential biomarkers of aflatoxin ingestion in dairy cows fed no sequestering agents. This study confirmed the protective effects of sequestering agents in dairy cows challenged with aflatoxin B1.Entities:
Keywords: aflatoxin; biomarker; dairy cows
Mesh:
Substances:
Year: 2019 PMID: 31779109 PMCID: PMC6950757 DOI: 10.3390/toxins11120693
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Partial least squares discriminant analysis score plots of (A) control vs. toxin groups, (B) control vs. clay groups, and (C) control vs. clay + S. cerevisiae fermentation product (YEA) groups.
Figure 2Variables ranked by variable importance in projection (VIP) between control and toxin groups (A), control and clay groups (B), and control and clay + S. cerevisiae fermentation product groups (C). Acylcarnitines: C12, C161, C3, C3OH, C12DC, C8, C5OH, C16OH, C181OH, C31, C4, C181, C12DC, C5MDC, C31, C141OH, C162, C3OH, C162OH, C8, C14, C142, C16OH, C2, C51, C5DC, C12, C61, C101, C4OH, C3, C9, C31, C12DC, C5MDC. Glycerophospholipids: LYSOC260, LYSOC240, PC401AA, LYSOC280, LYSOC281, PC402AA, LYSOC170, 202SM, 181SM, 161SM, LYSOC261, 161SMOH, PC322AA, PC401AA, LYSOC203.
The concentrations (µM) of plasma metabolites that were affected in dairy cows fed aflatoxin B1 with or without clay and SCFP 1-based sequestering agents.
| Item | Treatment 2 | SEM | ||||
|---|---|---|---|---|---|---|
| Control | T | CL | YEA | |||
| Alanine | 337 b | 284 c | 334 b | 462 a | 18.1 | 0.01 |
| Valine | 331 y | 312 y | 325 y | 387 x | 14.5 | 0.06 |
| Proline | 143 b | 127 b | 137 b | 194 a | 7.47 | 0.01 |
| Threonine | 152 b | 136 b | 140 b | 172 a | 7.82 | 0.01 |
| Leucine | 281 b | 227 b | 284 b | 362 a | 14.2 | 0.01 |
| Isoleucine | 129 b | 131 b | 128 b | 148 a | 6.30 | 0.03 |
| Aspartic acid | 23.5 y | 26.9 xy | 29.5 xy | 43.5 x | 5.62 | 0.09 |
| Glutamic acid | 236 b | 219 b | 206 b | 305 a | 9.95 | 0.01 |
| Arginine | 128 b | 96 c | 131 b | 159 a | 10.4 | 0.02 |
| Phenylalanine | 68.4 b | 71.1 b | 69.4 b | 83.1 a | 4.37 | 0.05 |
| Citrulline | 73.6 xy | 62.6 y | 81.0 x | 71.6 xy | 4.81 | 0.07 |
| Sarcosine | 1.83 xy | 1.74 xy | 1.50 y | 1.95 x | 0.12 | 0.06 |
| Lysine | 159 b | 173 ab | 170 ab | 194 a | 9.05 | 0.05 |
1Saccharomyces cerevisiae fermentation product–based sequestering agent (Diamond V, Cedar Rapids, IA), 2 T = control diet + aflatoxin B1 (AFB1, 1725 μg/d); CL = T + 200 g/d of sodium bentonite clay; YEA = CL + 35 g/d of Saccharomyces cerevisiae fermentation product (SCFP). a,b,c Within a row, treatment means with different superscripts differ (p ≤ 0.05). x,y Within a row, treatment means with different superscripts tend to differ, 0.05 < p ≤ 0.10.
Figure 3Receiver–operator characteristic curves of control vs. aflatoxin groups for (A) arginine and alanine and (B) arginine, alanine, methylhistidine, and citrulline.